Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · lung-landscapes@6

SRR6013532

— · cohortSQ2

17004820-dfeb-5ff0-a3c7-893578e28ff8

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
cohortSQ2
subtype
cohortSQ2

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • MYC_TARGETS_V1+0.480
  • E2F_TARGETS+0.470
  • MTORC1_SIGNALING+0.460
  • MYC_TARGETS_V2+0.420
  • OXIDATIVE_PHOSPHORYLATION+0.410
  • G2M_CHECKPOINT+0.400
  • REACTIVE_OXYGEN_SPECIES_PATHWAY+0.390
  • HYPOXIA+0.340
  • GLYCOLYSIS+0.330
  • EPITHELIAL_MESENCHYMAL_TRANSITION+0.320

Top 10 suppressed

  • UV_RESPONSE_DN-0.220
  • PROTEIN_SECRETION-0.170
  • INTERFERON_ALPHA_RESPONSE-0.160
  • HEME_METABOLISM-0.130
  • TGF_BETA_SIGNALING-0.130
  • ANDROGEN_RESPONSE-0.120
  • NOTCH_SIGNALING-0.100
  • BILE_ACID_METABOLISM-0.080
  • COMPLEMENT-0.060
  • INTERFERON_GAMMA_RESPONSE-0.060

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

8 twins match this tumor's tissue · 2 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
156218_S133
lung-landscapes@6
—cohortSQ10.848
2ULC1427T_S35
lung-landscapes@6
—cohortSQ20.802
3TCGA-22-1012-01A-01R-0692-07
lung-landscapes@6
—cohortSQ20.799
4TCGA-22-0944-01A-01R-0692-07
lung-landscapes@6
—cohortSQ20.796
5BD887C3F-0002-4EC8-B845-9B38E78A3906
brain-umap@2
——0.793
6BS_JZRM1S3T
medullo-epn-umap@date-based
MedMedulloblastoma0.789
7SRR6013551
lung-landscapes@6
—cohortSQ10.786
8TCGA-18-4086-01A-01R-1100-07
lung-landscapes@6
—cohortSQ20.783
920040035.Her2HRneg
breast-umap@18
—E0.780
10SJEPD001540_D1.RNA-Seq
medullo-epn-umap@date-based
EPNSupratentorial EPN0.780

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 37 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
MYC_TARGETS_V10.480Inavolisib— uncovered
E2F_TARGETS0.470Inavolisib— uncovered
MTORC1_SIGNALING0.460Inavolisib— uncovered
MYC_TARGETS_V20.420Idelalisib— uncovered
OXIDATIVE_PHOSPHORYLATION0.410Remibrutinib— uncovered
G2M_CHECKPOINT0.400Inavolisib— uncovered
REACTIVE_OXYGEN_SPECIES_PATHWAY0.390Inavolisib— uncovered
HYPOXIA0.340Idelalisib— uncovered
GLYCOLYSIS0.330Inavolisib— uncovered
EPITHELIAL_MESENCHYMAL_TRANSITION0.320Inavolisib— uncovered
APICAL_SURFACE0.300Temsirolimus— uncovered
WNT_BETA_CATENIN_SIGNALING0.280Inavolisib— uncovered
PANCREAS_BETA_CELLS0.250Cobimetinib— uncovered
CHOLESTEROL_HOMEOSTASIS0.220Remibrutinib— uncovered
UNFOLDED_PROTEIN_RESPONSE0.220Idelalisib— uncovered
HEDGEHOG_SIGNALING0.210Inavolisib— uncovered
APICAL_JUNCTION0.200Inavolisib— uncovered
P53_PATHWAY0.200Idelalisib— uncovered
PI3K_AKT_MTOR_SIGNALING0.190Inavolisib— uncovered
TNFA_SIGNALING_VIA_NFKB0.180Inavolisib— uncovered